It should be noted that the deregulation of EZH2 in neoplasms can also arise as a consequence of other mechanisms, besides EZH2 gene mutations, such as transcriptional overexpression, changes in splicing, e.g., due to serine/arginine-rich splicing factor 2 (SRSF2) mutations, and changes in its chromatin distribution [73]. This evidence concerns the gene EZH2 and neoplasm.